NAD+ Cell Regenerator

NAD+ Cell Regenerator

Life Extension4.7 (4,163 ratings)
Format:Capsule Quantity: 30 Capsule(s) · 30 servings
Goals
$40.50 $1.35 per serving

Product analysis

48 out of 100

NAD+ Cell Regenerator offers a focused nicotinamide riboside supplement at a moderate cost.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality20

The precise nutrient form is not fully identified in the ingredient description. That limits a direct comparison of form quality with other options.

Ingredient Transparency63

The declared nutrient amount is identified, but the ingredient form is unspecified. The description therefore makes quantity clearer than the precise preparation.

Value For Money60

The serving offers moderate value for its cost. It is reasonably priced rather than especially inexpensive.

Customer Satisfaction88

Customer ratings are very positive across thousands of reviews. That gives a broad picture of satisfaction without establishing cardiovascular benefits.

Product Focus30

The single-ingredient formula is focused, but its contribution to heart support remains uncertain. The serving has no established connection to the relevant cardiovascular measurements.

Format
Capsule
Container
30 Capsule(s)
Per serving
$1.35
Customer rating
4.7 · 4,163 ratings
Report analysis

Goals

Heart Health
Impact
Situational effect
C- Ingredient FitF PathwaysF EvidenceB Formulation Logic
Study evidence
Niacin Supportive 105 studies
Cardiovascular Support
Impact
Situational effect
C- Ingredient FitF PathwaysF EvidenceB Formulation Logic
Niacin · 300 mg
Study evidence
Niacin Supportive 136 studies
Skin Health
Impact
Situational effect
C- Ingredient FitF PathwaysF EvidenceB Formulation Logic
Study evidence
Niacin Supportive 61 studies

Ingredients

IngredientAmount per servingScore
NIAGEN Nicotinamide Riboside
300 mg 89
Gluten Free Adults 18–50
Report overview
Niacin · 300 mg OverallScore89
A+ Active Ingredient Quality & BioavailabilityA Dose, Safety & Label TransparencyC Value
Each serving supplies 300 mg of niacin at a moderate serving cost. The form is Nicotinamide Riboside. It is intended for NAD+ support.
How this ingredient is rated

Active Ingredient Quality & Bioavailability100

Nicotinamide riboside is a precursor used for the stated NAD+ goal. The source is a named NAD+ precursor.
Niacin Form & Goal Alignment
Nicotinamide riboside is a precursor used for the stated NAD+ goal.
Precursor Source Quality
The product names nicotinamide riboside, an NAD+ precursor.

Dose, Safety & Label Transparency92

A serving supplies 300 mg of niacin. Nicotinamide Riboside is named. The product is described as no-flush.
Clarity of Chemical Form
The form is Nicotinamide Riboside.
Form-Specific Dosage Efficacy
A serving supplies 300 mg of niacin.
Flush Risk & Safety Labeling
The product is described as no-flush.

Value60

The serving cost is moderate for this form of niacin.
Price Per Effective Serving
The serving cost is moderate for this form of niacin.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  2. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  3. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  4. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  5. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  6. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  7. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  8. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  9. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  10. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin
  11. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
    Hakozaki T; Minwalla L; Zhuang J; Chhoa M; Matsubara A; Miyamoto K; Greatens A; Hillebrand GG; Bissett DL; Boissy RE · The British journal of dermatology · 2002
    Randomized trial138 participantsSkin Health forNiacin
  12. Niacinamide: A B vitamin that improves aging facial skin appearance.
    Bissett DL; Oblong JE; Berge CA · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2005
    Randomized trial50 participantsSkin Health forNiacin
  13. The clinical anti-aging effects of topical kinetin and niacinamide in Asians: a randomized, double-blind, placebo-controlled, split-face comparative trial.
    Chiu PC; Chan CC; Lin HM; Chiu HC · Journal of cosmetic dermatology · 2008
    Randomized trial52 participantsSkin Health forNiacin
  14. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
    Chen AC; Martin AJ; Choy B; Fernández-Peñas P; Dalziell RA; McKenzie CA; Scolyer RA; Dhillon HM; Vardy JL; Kricker A; St George G; Chinniah N; Halliday GM; Damian DL · The New England journal of medicine · 2015
    Randomized trial386 participantsSkin Health forNiacin
  15. Nicotinamide for Skin Cancer Chemoprevention.
    Breglio KF; Knox KM; Hwang J; Weiss R; Maas K; Zhang S; Yao L; Madden C; Xu Y; Hartman RI; Wheless L · JAMA dermatology · 2025
    Cohort study33,822 participantsSkin Health forNiacin